Kairos Pharma, LTD.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| KAIROS PHARMA, LTD. | ||
| By: | /s/ John S. Yu | |
| John S. Yu | ||
| Chief Executive Officer and Chairman of the Board of Directors | ||
| Date: March 31, 2026 | Principal Executive Officer | |
|---|---|---|
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ John S. Yu | Chairman of the board of directors, | |
| John S. Yu | Chief Executive Officer | March 31, 2026 |
| (principal executive officer) | ||
| /s/ Doug Samuelson | Chief Financial Officer | |
| Doug Samuelson | (principal financial and accounting officer) | March 31, 2026 |
| /s/ Hyun W. Bae | Director | |
| Hyun W. Bae | March 31, 2026 | |
| /s/Hansoo Michael Keyoung | Director | |
| Hansoo Michael Keyoung | March 31, 2026 | |
| /s/ Rahul Singhvi | Director | |
| Rahul Singhvi | March 31, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.